Netlist Prevails In Federal Circuit Appeal Of Load Reduction Patents

IRVINE, Calif., July 26, 2017 /PRNewswire/ -- Netlist, Inc. (NASDAQ: NLST), today announced the U.S. Court of Appeals for the Federal Circuit vacated and remanded earlier decisions from the U.S. Patent Trial and Appeal Board (PTAB) which invalidated certain claims of Netlist's U.S. Patent Numbers 7,881,150 ("'150 Patent") and 8,081,536 ("'536 Patent"). 

The '150 and '536 Patents cover fundamental load reduction technologies used in various server memory products such as Load Reduced Dual Inline Memory Modules (LRDIMMs).  In its ruling, the Federal Circuit sided with Netlist on two of the three issues raised on appeal, finding the PTAB's earlier decisions were based on an erroneous interpretation of the patent claims.  The Federal Circuit vacated the earlier decisions and remanded the cases back to the PTAB for further proceedings.

"We are very pleased with today's ruling from the Federal Circuit. The strength of the company's intellectual property reflects the early ground-breaking work of Netlist's engineers in high-performance server memory, such as the load reduction technology at issue in this case," said Netlist Chief Executive Officer, C.K. Hong. "This victory continues the exceptional track record that our legal team has built defending Netlist patents in challenges before the PTAB."

Netlist has asserted these patents against SanDisk and Diablo Technologies as part of a seven-patent lawsuit in the U.S. District Court of the Northern District of California against the ULLtraDIMM product.  The defendants in that action filed multiple Inter Partes Reviews ("IPRs") against all seven asserted patents.  Netlist ultimately prevailed in the final written decisions from IPRs in five of the seven patents, with negative decisions only on the '150 and '536.  Yesterday's Federal Circuit ruling vacates the negative decisions as to the IPRs filed by Diablo.  Appeals from IPRs filed by SanDisk are still pending before the Federal Circuit.

About Netlist, Inc.
Netlist is a leading provider of high-performance modular memory subsystems serving customers in diverse industries that require superior memory performance to empower critical business decisions. Flagship products NVvault® and EXPRESSvault® enable customers to accelerate data running through their servers and storage and reliably protect enterprise-level cache, metadata and log data by providing near instantaneous recovery in the event of a system failure or power outage. HybriDIMM™, Netlist's next-generation storage class memory product, addresses the growing need for real-time analytics in Big Data applications and in-memory databases. Netlist holds a portfolio of patents, many seminal, in the areas of hybrid memory, storage class memory, rank multiplication and load reduction. Netlist is part of the Russell Microcap® Index.  To learn more, visit www.netlist.com.

Safe Harbor Statement
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than historical facts and often address future events or the future performance of Netlist. Forward-looking statements contained in this news release include statements about Netlist's ability to execute on its strategic initiatives. All forward-looking statements reflect management's present expectations regarding future events and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed in or implied by any forward-looking statements. These risks, uncertainties and other factors include, among others: risks related to Netlist's plans for its intellectual property, including its strategies for monetizing, licensing, expanding, and defending its patent portfolio; risks associated with patent infringement litigation initiated by Netlist, such as its ongoing proceedings against SK hynix Inc., or by others against Netlist, as well as the costs and unpredictability of any such litigation; risks associated with Netlist's product sales, including the market and demand for products sold by Netlist and its ability to successfully develop and launch new products that are attractive to the market; the success of product, joint development and licensing partnerships, including its relationship with Samsung Electronics Co., Ltd.; the competitive landscape of Netlist's industry; and general economic, political and market conditions.  These and other risks and uncertainties are described in Netlist's quarterly report on Form 10-Q filed on May 16, 2017, and subsequent filings with the U.S. Securities and Exchange Commission it makes from time to time. Given these risks, uncertainties and other important factors, undue reliance should not be placed on these forward-looking statements. These forward-looking statements represent Netlist's estimates and assumptions only as of the date made, and except as required by law, Netlist undertakes no obligation to revise or update any forward-looking statements for any reason.

For more information, please contact:

Brainerd Communicators, Inc. 
Mike Smargiassi/ William Metzger 
NLST@braincomm.com 
(212) 986-6667 

                                 

View original content:http://www.prnewswire.com/news-releases/netlist-prevails-in-federal-circuit-appeal-of-load-reduction-patents-300494356.html

SOURCE Netlist, Inc.

SKYCOP Urges UK’s CAA to Act: British Airways Owe up to EUR45 Million to Passengers

LONDON, July 26, 2017 /PRNewswire/ --

Following an "IT failure" that struck the British Airways' network on the 27th of May, an estimated 75,000 were left stranded at airports across Europe. SKYCOP has now approached the United Kingdom Civil Aviation Authority in order to receive answers from the airline as to when the debt, which might be as big as 45 million euros, will be paid to those passengers left without flights.  

After the aforementioned incident that paralysed British Airways' network back in May, the company standing up for passengers and their rights in a fight against airline misbehaviour towards flight refunds, SKYCOP, has received numerous  requests from the unlucky passengers asking for what is rightfully theirs. 

As Marius Stonkus, the CEO of global claim platform http://www.skycop.co.uk explains, the "IT glitch" not only caused major issues and costs to passengers but also created chaos at the airports, as well as damaging the reputation of the whole industry.

"I have personally written and sent out a letter to the CEO of British Airways, Alex Cruz, asking for answers on the compensation status - after all, they might owe up to €45 million, for flight's sake! Honestly, it just amazes me, how such a previously reputable company has now fallen to such lows - thousands of passengers waiting for their answers on the claims, let alone the low blow that the whole industry has experienced- trust has been lost in airlines worldwide. Since this 'IT failure' does not fall under extraordinary circumstances laid out in the EU law, we had no other choice in getting carrier's attention but to address the CAA and ask them using their competence and influence urge British Airways to give honest answers to their stranded passengers," explains Marius Stonkus.

About SKYCOP: 

SKYCOP is a company, standing up for passengers and their rights in a fight against airline misbehaviour towards flight refunds. 

Company's global online platform http://www.skycop.com offers hassle-free claim management for delayed, cancelled or overbooked flights to passengers across the world.

SKYCOP and its team of professionals with 10+ years of experience in aviation business, law and credit management is keen on restoring the justice in airline-flyer relationship and getting what legitimately belongs to those deprived of their personal rights.  

Claim what's yours now: http://www.skycop.com

Follow us on: 
Facebook
LinkedIn

For more information, please contact:
press@skycop.com 
+370-685-72454



 

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Asanko Gold Inc. – AKG

NEW YORK, July 25, 2017 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Asanko Gold Inc. (NYSE: AKG) from October 24, 2014 through May 31, 2017, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Asanko Gold investors under the federal securities laws.

To join the Asanko Gold class action, go to http://www.rosenlegal.com/cases-1139.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Asanko Gold's Mineral Resource Estimates are flawed; (2) some of Asanko Gold's resources models exhibit signs that they have been "smeared," which would cause estimates of their ore contents to be inflated; and (3) as a result, Asanko Gold's public statements were materially false and misleading at all relevant times.

On June 30, 2016, hedge fund K2 & Associates published a report asserting, among other things that Asanko Gold's gold resources "don't add up" and appear to be over-inflated by a factor of two. On this news, shares of Asanko Gold fell $0.15 per share or over 3% to close at $3.81 per share on June 30, 2016, damaging investors. On May 31, 2017, research firm Muddy Waters published a report asserting, among other things, that: (1) Asanko Gold made investments based on flawed geology in Nkran, its satellite pits and Esaase that Muddy Waters believes "will never be recovered"; and (2) there are indicia that some of Asanko Gold's resources models have been "smeared", which would cause estimates of their ore contents to be inflated. On this news, shares of Asanko Gold fell $0.58 per share or over 31% to $1.29 per share during intraday trading on May 31, 2017 and were halted, further damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 31, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1139.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

View original content:http://www.prnewswire.com/news-releases/equity-alert-rosen-law-firm-announces-filing-of-securities-class-action-lawsuit-against-asanko-gold-inc--akg-300494098.html

SOURCE Rosen Law Firm, P.A.

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zoompass, Inc. – ZPAS

NEW YORK, July 25, 2017 /PRNewswire-USNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zoompass Holdings, Inc. (OTC: ZPAS) from April 24, 2017 and May 24, 2017, both dates inclusive (the "Class Period"). The lawsuit seeks to recover damages for Zoompass investors under the federal securities laws.

To join the Zoompass class action, go to http://www.rosenlegal.com/cases-1137.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) Zoompass unlawfully engaged in a scheme to promote its stock; (2) discovery of the foregoing conduct would subject Zoompass to heightened regulatory scrutiny and potential criminal sanctions; and (3) that as a result, Zoompass' public statements were materially false and misleading at all relevant times.

On May 9, 2017, Zoompass disclosed that it had been "made aware of and requested by the OTC Markets Group, Inc. to comment on recent trading and potential promotional activity." On May 25, 2017, Seeking Alpha published an article alleging that Zoompass had erroneously denied its involvement with a scheme designed to promote Zoompass' stock and purposely conceal Zoompass' CEO was involved in a pump-and-dump scheme. On this news, shares of Zoompass fell $0.70 per share or over 23% to close at $2.25 per share on May 25, 2017, damaging investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 31, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1137.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY  10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

View original content with multimedia:http://www.prnewswire.com/news-releases/equity-alert-rosen-law-firm-announces-filing-of-securities-class-action-lawsuit-against-zoompass-inc--zpas-300494085.html

SOURCE Rosen Law Firm, P.A.

Block & Leviton Reminds Ocular Therapeutix, Inc. (OCUL) Shareholders Of Important Deadline In Securities Fraud Class Action And Encourages Them To Contact The Firm

BOSTON, July 25, 2017 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) of the September 5, 2017 lead plaintiff deadline in the securities fraud class action against the Company and certain of its executives.

On Jul 6, 2017, near the close of trading, the investor website Seeking Alpha published an article entitled "Ocular: A Poke In The Eye," reporting that Ocular is on "the brink of collapse" and that they may be "misleading investors" about ongoing manufacturing issues and the Company's communications with the FDA about those issues.

On this news, Ocular's stock fell more than 30% to close at $7.12 on July 7, 2017, and has continued to slide below $6.50 per share, causing tens of millions in losses to shareholders.

If you purchased or otherwise acquired Ocular securities between May 5, 2017 through July 6, 2017 (the "Class Period") and have questions about your legal rights or possess information relevant to this investigation, please contact attorney Bradley Vettraino at (617) 398-5600, by email at bradley@blockesq.com, or by visiting www.blockesq.com/ocular.  

The class action lawsuit alleges that throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times.

If you wish to serve as a lead plaintiff, you must move the Court no later than September 5, 2017.  As a member of the class, you may seek to file a motion to serve as a lead plaintiff or take no action and remain an absent class member. If you wish to become involved in the litigation or have questions about your legal rights, please contact attorney Bradley Vettraino at (617) 398-5600, by email at bradley@blockesq.com.

Confidentiality to whistleblowers or others with information relevant to this investigation is assured.

Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

This notice may constitute attorney advertising.

CONTACT:

Block & Leviton LLP
Bradley J. Vettraino
155 Federal Street, Suite 400
Boston, MA 02110
(617) 398-5600
bradley@blockesq.com

View original content:http://www.prnewswire.com/news-releases/block--leviton-reminds-ocular-therapeutix-inc-ocul-shareholders-of-important-deadline-in-securities-fraud-class-action-and-encourages-them-to-contact-the-firm-300494047.html

SOURCE Block & Leviton LLP

Bio Pharma Giant — Celgene — Settles Case Alleging Marketing Violations For $280 Million

LOS ANGELES, July 25, 2017 /PRNewswire-USNewswire/ -- On the eve of trial, Bio Pharma giant, Celgene Corporation, has agreed to pay $280 million to resolve allegations it sold and promoted its blockbuster drugs, Thalomid and Revlimid, in violation of federal and state laws.

The case, U.S. ex rel. Brown v. Celgene, CV 10-03165 (RK) (C.D. Cal.), was brought by a former Celgene sales representative, Beverly Brown, under the federal False Claims Act (FCA) and state analogues.  The federal civil settlement agreement encompasses allegations Celgene: (1) promoted Thalomid and Revlimid for off-label uses that were not approved by the FDA, were – in many cases – unsafe, and were not properly reimbursable by federal insurance programs; and (2) offered illegal kickbacks to a wide range of entities in an effort to influence health care providers to select its products for use, regardless of whether they were reimbursable by federal or state health care programs or were medically necessary.  The settlement also encompasses allegations that Celgene: (1) concealed or downplayed adverse events associated with use of Thalomid and Revlimid; and (2) improperly influenced the content of published drug compendia entries, medical literature, clinical studies and NCCN guidelines for Thalomid and Revlimid to support uses of these drugs not supported by medical science, including by making payments to physicians who had influence over the content of published drug compendia entries.

Ms. Brown brought her case in 2010 and it remained under seal – and under investigation by the government for 4 years – until 2014 when the government decided not to pursue the case.

Pursuing the case on her own, the $280 million resolution marks the second largest recovery in a non-intervened FCA case, largest recovery against a pharmaceutical company in a non-intervened case where core allegations were based on off-label promotion, and largest recovery involving a manufacturer of cancer drugs.

Originally passed by Congress and signed into law in 1864, modern day federal and state false claims acts allow whistleblowers – known as "relators" – to bring suit in the name of government against individuals or entities that caused the fraudulent or improper expenditure of government monies.

The litigation involved the review of millions of documents, briefing of numerous discovery motions and potentially case dispositive motions, taking of roughly 40 depositions, and analysis by leading medical experts, pharmaceutical economics experts, and conflicts of interest and medical ethics experts.  Celgene alone tendered 13 experts.  This undertaking makes this one of the most extensively litigated pharmaceutical cases brought under the FCA.

At the culmination of the discovery period, on December 28, 2016, the United States District Court in Los Angeles (Judge George King) issued an order denying summary in part, allowing the case to proceed to trial against Celgene on claims of off-label promotion.

In his Opinion, Judge King noted that "Celgene understood that its promotional efforts were successful in causing physicians to write prescriptions."  The Opinion also said that "hundreds of thousands of claims for off-label uses of Thalomid and Revlimid were submitted to Medicare and other government programs during the time when Celgene was promoting these drugs off-label."

"In an era where drug prices are out of control and too many people are prescribed unnecessary medications, cases like Celgene function as critical oversight of  industry which purportedly serves a healthcare function but way too often is driven by Wall Street goals, said Reuben Guttman, of Guttman, Buschner & Brooks PLLC (GBB) and counsel to Beverly Brown.  His partner, Justin Brooks, added that discovery in the case identified new paradigms for pharmaceutical fraud that will influence investigation and litigation of future False Claims Act cases.

In addition to GBB, the Brown litigation team included the firms of Bienert, Miller & Katzman ("BMK") of San Clemente California, Richard A. Harpootlian, P.A. of Columbia, South Carolina, and former federal Judge and Harvard Law Professor, Nancy Gertner, from Boston, Massachusetts.  Their work was instrumental to the case's success.

GBB lawyers on the case include firm partners Reuben Guttman, Traci Buschner, and Justin Brooks as well as Of Counsel Dan Guttman, Liz Shofner, Caroline Poplin, MD/JD, and Paul Zwier, who is also an evidence expert and Professor at Emory Law School.

Richard Harpootlian and Chris Kenney were the principle counsel on the case from Richard A. Harpootlian, P.A. Tom Bienert, Mike Williams, Ariana Hawbecker, and Ali Matin were the principal lawyers from BMK.

For attorneys at Guttman, Buschner & Brooks PLLC, the settlement marks another positive result in a string of cases under the False Claims Act.  With the addition of this settlement, GBB attorneys have represented whistleblowers in cases recovering nearly $5.5 billion for the federal government and state governments. 

This action also marks another significant recovery for Richard A. Harpootlian, P.A., which holds the record for the largest bounty paid to a relator in a South Carolina whistleblower action and has recovered hundreds of millions of dollars for federal and state governments.

Bienert, Miller & Katzman, PLC  (BMK) is a trial firm that was uniquely qualified to work with the other firms in this case.  Consisting of former federal and state prosecutors, federal public defenders and large firm trained attorneys, its lawyers collectively have hundreds of jury and court trials.  The result in this case marks a string of multi-million dollar trials and settlements for its clients.  BMK continues to advocate for a number of significant whistleblower suits, combining nationally recognized expertise in a boutique legal setting, ensuring personalized attention to their cases.

 

View original content:http://www.prnewswire.com/news-releases/bio-pharma-giant----celgene----settles-case-alleging-marketing-violations-for-280-million-300494044.html

SOURCE Guttman, Buschner & Brooks PLLC

Union of Concerned Scientists: Trump Administration Sidelines Science First Six Months in Office

WASHINGTON, July 25, 2017 /PRNewswire/ -- Since Donald Trump took the oath of office six months ago, his administration and congressional allies have undermined the vital role science plays in policy decisions, according to a new report by the Union of Concerned Scientists (UCS).

The report, "Sidelining Science Since Day One: How the Trump Administration Has Harmed Public Health and Safety in Its First Six Months," analyzes the ways the federal government uses science to make policy and how the administration has opened the door to new levels of political interference in the process.

"There's a clear pattern here," said Gretchen Goldman, research director for the Center for Science and Democracy at UCS and a report co-author. "This administration and its allies in Congress are pushing science aside, and in the process, they're putting the public at risk."

The report documents that the Trump administration has dismissed key scientific advisors, left critical science positions vacant, restricted federal scientists' ability to speak publicly, denied public access to taxpayer-funded information, and ignored scientific evidence in order to delay or roll back vital public safeguards. In many cases, they have appointed officials with close ties to the industries they will oversee and a record of attacking the very agencies they have been put in charge of.

"If we're not using science to make policy, these decisions will be made on behalf of industry lobbyists," said Andrew Rosenberg, director of the Center for Science and Democracy and a former regional administrator for NOAA's National Marine Fisheries Service. "The federal government can't make good decisions without good independent science, but this administration has created a hostile environment for research."

From weather monitoring to food safety inspection to efforts to fight epidemic diseases, federal science matters—and undermining it puts Americans at risk.

UCS is mobilizing scientists and the public to challenge the administration when it ignores the facts or promotes disinformation. To encourage federal scientists to speak out, the organization has established a new legal protection fund for federal employees who help expose wrongdoing.  

"The actions the administration has taken in just six months have already put people at risk," said UCS President Ken Kimmell, a former commissioner of the Massachusetts Department of Environmental Protection. "The damage they do could last for years to come."

View original content:http://www.prnewswire.com/news-releases/union-of-concerned-scientists-trump-administration-sidelines-science-first-six-months-in-office-300493914.html

SOURCE Union of Concerned Scientists

TransPerfect Employees and Members of Citizens for a Pro-Business Delaware Protest Involvement of Lionsbridge in the TransPerfect Sales Process at Judge Bouchard’s Speaking Engagement in New York City

Protestors call on Judge Bouchard to update employees on mediation and rule out Lionsbridge as potential buyer over concerns about moving almost all of their 5,000 jobs offshore

NEW YORK, July 25, 2017 /PRNewswire/ -- Last Friday, July 21, TransPerfect employees and members of Citizens for a Pro-Business Delaware (CPBD) rallied in New York City to continue voicing their opposition against the forced sale of TransPerfect and asked Judge Bouchard to eliminate Lionsbridge from being involved in the sales process. Court appointed Chancellor Andre Bouchard spoke at Practicing Law Institute's (PLI) event, Delaware Law Development 2017, where dozens of TransPerfect employees and CPBD members showed up to protest his unprecedented ruling to break-up and sell the successful, profitable TransPerfect and make their voices heard. Over the last two weeks, employees have heard that Lionsbridge is a potential buyer. As all but 300 of their 5,000 jobs are overseas, TransPerfect employees are concerned over the loss or outsourcing of the majority of their jobs. 

"There is a heist being committed against the employees of TransPerfect, and we can send not stand by and let these 4,000 jobs be moved overseas," said Chris Coffey, Campaign Manager of Citizens for a Pro-Business Delaware. "It is critical that Chancellor Bouchard understands the views of and sees firsthand the thousands of employees whose lives he is upending and the families his actions hurt. Additionally, we ask that Judge Bouchard look at the runaway spending of Custodian Pincus. They have spent over $20 million on consultants while family premiums continue to skyrocket. It is wrong and must stop." 

Protestors chanted "Save TransPerfect, save our jobs" on the sidewalk outside of Chancellor Bouchard's speaking engagement at the PLI event.  They wore blue CPBD t-shirts and held signs that read "Save TransPerfect.  Don't Let Courts Control Our Companies."

Despite multiple requests, Chancellor Bouchard has failed to provide an update on his earlier recommendation of mediation. "We all are hoping that mediation can work, but all we have heard from the custodian, Robert Pincus, is that it has failed," said Coffey.  "We call on Chancellor Bouchard to fulfill his responsibility to provide us with a full update."

Citizens for a Pro-Business Delaware is a group made up of more than 2,200 members including employees of the global translation services company TransPerfect as well as concerned Delaware residents, business executives and others. It formed in April of 2016 to focus on raising awareness with Delaware residents, elected officials, and other stakeholders about these issues.

For more information on Citizens for a Pro-Business Delaware visit DelawareForBusiness.org.

Contact: Sloane Whelan, sw@kofapublicaffairs.com

View original content:http://www.prnewswire.com/news-releases/transperfect-employees-and-members-of-citizens-for-a-pro-business-delaware-protest-involvement-of-lionsbridge-in-the-transperfect-sales-process-at-judge-bouchards-speaking-engagement-in-new-york-city-300493779.html

SOURCE Citizens for a Pro-Business Delaware

D.C. Appeals Court Strikes Down ‘Good Reason’ CCW Law – SAF

BELLEVUE, Wash., July 25, 2017 /PRNewswire-USNewswire/ -- The Second Amendment Foundation today won a significant court victory against "good reason" requirements for concealed carry when the U.S. Court of Appeals for the District of Columbia issued a permanent injunction against enforcement of such a requirement in Washington, D.C.

The 2-1 ruling, written by Judge Thomas Beall Griffith, a 2005 George W. Bush appointee, declared that, "At the Second Amendment's core lies the right of responsible citizens to carry firearms for personal self-defense beyond the home, subject to longstanding restrictions…The District's good-reason law is necessarily a total ban on exercises of that constitutional right for most D.C. residents. That's enough to sink this law under (the 2008 U.S. Supreme Court's Heller ruling)."

"Today's ruling contains some powerful language that affirms what we have argued for many years, that requiring a so-called 'good cause' to exercise a constitutionally-protect right does not pass the legal smell test," said SAF founder and Executive Vice President Alan M. Gottlieb. "We're particularly pleased that the opinion makes it clear that the Second Amendment's core generally covers carrying in public for self-defense."

The 31-page majority opinion also said that the District's "good cause" requirement was essentially designed to prevent the exercise of the right to bear arms by most District residents. Thus, it amounts to a complete prohibition, and that does not pass muster under the 2008 Heller ruling that struck down the District's 30-year handgun ban.

"The good-reason law," Judge Griffith wrote, "is necessarily a total ban on most D.C. residents' right to carry a gun in the face of ordinary self-defense needs…"

"To read the majority opinion and not come away convinced that such 'good reason' or 'good cause' requirements are just clever ways to prevent honest citizens from exercising their rights is not possible," Gottlieb stated. "To say we are delighted with the ruling would be an understatement. We are simply more encouraged to keep fighting, winning firearms freedom one lawsuit at a time."

The case is Wrenn v. District of Columbia.

The Second Amendment Foundation (www.saf.org) is the nation's oldest and largest tax-exempt education, research, publishing and legal action group focusing on the Constitutional right and heritage to privately own and possess firearms. Founded in 1974, The Foundation has grown to more than 650,000 members and supporters and conducts many programs designed to better inform the public about the consequences of gun control.

 

View original content:http://www.prnewswire.com/news-releases/dc-appeals-court-strikes-down-good-reason-ccw-law--saf-300493768.html

SOURCE Second Amendment Foundation

Morgan & Morgan Turns Initial $0 Offer From Insurance Company into $2.28M Verdict for Woman Hurt in Trip-and-Fall

National Law Firm Scores a $2.28M Verdict for Client Whose Pre-Existing Condition Was Exacerbated by Trip-and-Fall Down Stairs in a Negligent Apartment Complex

JACKSONVILLE, Fla., July 25, 2017 /PRNewswire/ -- Morgan & Morgan, the nation's leading plaintiffs' firm, is immensely proud to announce its successful recovery of a $2,228,679 jury verdict on behalf of a client who seriously injured her back after a trip-and-fall in an apartment complex.

Attorney Tim Moran, assisted by attorney Ashley Winstead, represented the client, Rosetta Harris, who struggled with a pre-existing medical condition that caused her back pain for over seven years prior to the accident. Ms. Harris's pre-existing condition was greatly exacerbated by the painful trip-and-fall down a poorly-maintained set of stairs in the apartment complex, according to the complaint.

In the aftermath of her accident, her injuries required a visit to the Emergency Room, as well as costly long-term medical treatments such as chiropractic care and pain management.

Despite the high cost of her medical treatment, Ms. Harris's insurance company initially offered her nothing, blaming her serious back injury on her pre-existing condition, rather than the trip-and-fall that only occurred due to the negligent conditions of the apartment complex building's stairway.

The defense's highest pre-trial offer — $50,000 — did not even begin to cover Ms. Harris's prior medical expenses caused by her accident, let alone future treatment. That's why Moran took the fight to court to get his client the fair verdict she deserved to heal from her injuries.

The jury disagreed with the insurance company's assessment of Ms. Harris's injuries, and instead sided with Moran's winning argument. As a result, the jurors awarded a jury verdict of $2.28M to compensate the client for her pain and suffering, past and future medical bills, and other damages.

Furthermore, the jury found the apartment complex where the Ms. Harris's accident took place to be 100 percent at-fault for the injuries she suffered due to negligence on the property.

"Ms. Harris was seriously injured as a result of falling down the apartment complex's negligently maintained steps, and it was apparent that no one at the apartment complex took her injuries seriously," said Moran. "I am so glad the jury took her case seriously, and returned a fair and just verdict, which will allow Ms. Harris to obtain the future medical care she will require, as well as compensate her for the effects the injuries from the fall have had on her life."

The case is Rosetta Harris vs. PBH Mayport, Llc, d/b/a Promenade at Mayport and B H Management Services, LLC, case number 16-2015-CA-2989, in the Circuit Court, Fourth Judicial Circuit, in and for Duval County, Florida.

ABOUT MORGAN & MORGAN                                                      

Morgan & Morgan, a national plaintiff's law firm fighting for the people, not the powerful, has recovered more than $4 billion for more than 200,000 clients. The firm has more than 350 attorneys in about 40 offices in 11 states. With the support of nearly 2,000 employees, the firm's attorneys represent clients in a wide range of practice areas — from personal injury, workers' compensation, and medical malpractice cases to labor and employment, mesothelioma, and product liability lawsuits to national mass torts and class actions.                                                         

For more information, contact:

Karine Lim / Erika Nedwell
Morgan & Morgan, P.A
klim@forthepeople.com / enedwell@forthepeople.com
212-738-6265 / 212-738-6254

 

View original content with multimedia:http://www.prnewswire.com/news-releases/morgan--morgan-turns-initial-0-offer-from-insurance-company-into-228m-verdict-for-woman-hurt-in-trip-and-fall-300493756.html

SOURCE Morgan & Morgan